Post-translational processing of beta-secretase in Alzheimer's disease

Proteomics. 2005 Apr;5(6):1533-43. doi: 10.1002/pmic.200401185.

Abstract

Beta-amyloid is released into the brains of Alzheimer's patients, where it aggregates and causes damage to neurons. It is cleaved proteolytically from a large transmembrane glycoprotein amyloid precursor protein by a membrane-bound protease, known as beta-secretase identified previously as the acid protease, Asp-2. We have shown previously that beta-secretase is up-regulated by increased intracellular cholesterol, and down-regulated by cholesterol biosynthesis inhibition. Here we show using mass spectrometry that discrete changes in the glycosylation and palmitoylation of beta-secretase occur when cells expressing it are treated with statins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / enzymology*
  • Alzheimer Disease / genetics
  • Amyloid Precursor Protein Secretases
  • Amyloid beta-Protein Precursor / metabolism
  • Anticholesteremic Agents / pharmacology
  • Aspartic Acid Endopeptidases
  • Cell Line
  • Cholesterol / pharmacology
  • Endopeptidases / chemistry
  • Endopeptidases / metabolism*
  • Glycoside Hydrolases / metabolism
  • Glycosylation
  • Humans
  • Lovastatin / pharmacology
  • Mass Spectrometry
  • Membrane Microdomains / enzymology
  • Mutation
  • Palmitates / metabolism
  • Protein Processing, Post-Translational
  • Recombinant Proteins / chemistry

Substances

  • Amyloid beta-Protein Precursor
  • Anticholesteremic Agents
  • Palmitates
  • Recombinant Proteins
  • Cholesterol
  • Lovastatin
  • Glycoside Hydrolases
  • Amyloid Precursor Protein Secretases
  • Endopeptidases
  • Aspartic Acid Endopeptidases
  • BACE1 protein, human